2020
Study design and implementation of the PRecision Medicine In MEntal health Care (PRIME Care) Trial
Oslin DW, Chapman S, Duvall SL, Gelernter J, Ingram E, Kranzler HR, Lehmann LS, Lynch JA, Lynch KG, Pyne JM, Shih MC, Stone A, Thase ME, Wray LO. Study design and implementation of the PRecision Medicine In MEntal health Care (PRIME Care) Trial. Contemporary Clinical Trials 2020, 101: 106247. PMID: 33316457, DOI: 10.1016/j.cct.2020.106247.Peer-Reviewed Original ResearchConceptsMajor depressive disorderPGx test resultsRandomized clinical trialsClinical trialsPGx testingHealth care cost implicationsUtility of PGxRoutine clinical carePragmatic randomized clinical trialsEpisode of careHealth care trialsPrecision medicineHealth care providersPrecision medicine approachPatient care costsImplementation science methodsCare trialsMedication selectionPsychotropic medicationsProvider educationDepressive disorderPatient outcomesPharmacogenetic testingCare providersClinical care
2007
Variation in GABRA2 Predicts Drinking Behavior in Project MATCH Subjects
Bauer LO, Covault J, Harel O, Das S, Gelernter J, Anton R, Kranzler HR. Variation in GABRA2 Predicts Drinking Behavior in Project MATCH Subjects. Alcohol Clinical And Experimental Research 2007, 31: 1780-1787. PMID: 17949392, PMCID: PMC3169387, DOI: 10.1111/j.1530-0277.2007.00517.x.Peer-Reviewed Original ResearchConceptsTwelve-step facilitationMotivational enhancement therapyCognitive behavioral therapyPsychosocial treatmentsSingle nucleotide polymorphismsAlcohol dependenceGABRA2 single nucleotide polymorphismsMulti-center randomized clinical trialHeavy drinkingRandomized clinical trialsLow-risk allelesPost-treatment periodPresent studyClinical trialsLower riskEuropean-American subjectsAlcoholism treatmentBehavioral therapyGABRA2 genotypeGABRA2 geneEnhancement therapyLower daily probabilityDrinking outcomesGenetic vulnerabilityPrevious studies